

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. DOI: 10.1056/NEJMoa2034577

SUPPLEMENTARY APPENDIX

List of Investigators	2
Table S1 	8
Table S2 Baseline Comorbidities.....	9
Table S3 Participants Reporting at Least 1 Adverse Event from Dose 1 (All Enrolled Participants).	10
Table S4 Vaccine Efficacy from 7 Days after Dose 2 by Underlying Comorbidities among Participants without Evidence of Infection Prior to 7 Days after Dose 2.	11
Table S5 Vaccine Efficacy of Severe COVID-19 Occurrence after Dose 1 (All-Available Efficacy Population).....	12

List of Investigators

Name	Institute	Location
Aberg, Judith	Icahn School of Medicine at Mount Sinai	New York, NY, USA
Adams, Mark	Central Kentucky Research Associates	Lexington, KY, USA
Addo, Marylyn	Universitätsklinikum Hamburg-Eppendorf	Hamburg, Germany
Akhan, Sila	Kocaeli University Med	Kocaeli, Turkey
Albertson, Timothy	University of California, Davis	Sacramento, CA, USA
Al-Ibrahim, Mohamed	SNBL Clinical Pharmacology Center	Baltimore, MD, USA
Altın, Sedat	Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital	Istanbul, Turkey
Anderson, Corey	Clinical Research Consortium	Tempe, AZ, USA
Andrews, Charles	Diagnostics Research Group	San Antonio, TX, USA
Aranha Camargo, Luis	Hospital Israelita Albert Einstein	Sao Paulo, Brazil
Arora, Samir	Aventiv Research	Columbus, OH, USA
Balik, Ismail	Ankara University Medical School	Ankara, Turkey
Barnett, Elizabeth	Boston Medical Center	Boston, MA, USA
Bauer, George	Benchmark Research	Metairie, LA, USA
Baumann-Noss, Sybille	CRS Clinical Research Services Berlin	Berlin, Germany
Baumgarten, Axel	Zentrum für Infektiologie Berlin Prenzlauer Berg (ZIBP)	Berlin, Germany
Bedel, Gary	Prestige Clinical Research	Franklin, OH, USA
Berhe, Mezgebe	North Texas Infectious Diseases Consultants	Dallas, TX, USA
Bradley, Paul	Meridian Clinical Research	Savannah, GA, USA
Brandon, Donald	California Research Foundation	San Diego, CA, USA
Brune, Daniel	Optimal Research	Peoria, IL, USA
Brunke, Mareile	Klinische Forschung Hannover-Mitte	Hannover, Germany
Buitrago, Martha	Snake River Research	Idaho Falls, ID, USA
Burgher, Abram	The Pain Center of Arizona	Peoria, AZ, USA
Butcher, Bain	Sterling Research Group	Cincinnati, OH, USA
Butuk, David	Solaris Clinical Research	Meridian, ID, USA
Cannon, Kevin	PMG Research of Wilmington	Wilmington, NC, USA
Cardona, Jose	Indago Research and Health Center	Hialeah, FL, USA
Cavelli, Rachael	State University of New York Upstate Medical University	Syracuse, NY, USA
Chalhoub, Fadi	CNS Healthcare	Jacksonville, FL, USA
Chambers, Christopher	Thomas Jefferson University	Philadelphia, PA, USA
Chevts, Julia	Klinische Forschung Karlsruhe	Karlsruhe, Germany
Christensen, Shane	J. Lewis Research	Salt Lake City, UT, USA
Christensen, Tom	Waterway Family Medicine	Little River, SC, USA
Chu, Laurence	Benchmark Research	Austin, TX, USA
Cockerham, Leslie	Froedtert Hospital	Milwaukee, WI, USA
Coleman, Stephen	J. Lewis Research	Salt Lake City, UT, USA
Cox, Jeremy	San Geronio Memorial Hospital	Banning, CA, USA
Cox, Steven	Lynn Institute of Norman	Norman, OK, USA
Creech, C. Buddy	Vanderbilt University	Nashville, TN, USA
Crook, Gretchen	Austin Regional Clinic: ARC Wilson Parke	Austin, TX, USA
Davis, Matthew	Rochester Clinical Research	Rochester, NY, USA
Davit, Rajesh	Sterling Research Group	Cincinnati, OH, USA
de St. Maurice, Annabelle	UCLA Health	Los Angeles, CA, USA
Denham, Douglas	Clinical Trials of Texas (CTT)	San Antonio, TX, USA

Dever, Michael	Clinical Neuroscience Solutions	Orlando, FL, USA
Donskey, Curtis	Louis Stokes Cleveland VA Medical Center	Cleveland, OH, USA
Doust, Matthew	Hope Research Institute	Phoenix, AZ, USA
Dunn, Michael	Quality Clinical Research	Omaha, NE, USA
Earl, John	PMG Research of Hickory	Hickory, NC, USA
Eder, Frank	United Medical Associates - Meridian Clinical Research	Binghamton, NY, USA
Eich, Andreas	IKF Pneumologie	Frankfurt, Germany
El-Shahawy, Mohamed	Academic Medical Research Institute	Los Angeles, CA, USA
Ensz, David	Meridian Clinical Research	Dakota Dunes, SD, USA
Erdoğan, Şebnem	Ankara Training and Research Hospital	Ankara, Turkey
Essink, Brandon	Meridian Clinical Research	Omaha, NE, USA
Falcone, Robert	Amici Clinical Research	Raritan, NJ, USA
Falkowski, Stephen	Southeast Clinical Research	Chiefland, FL, USA
Farrington, Cecil	PMG Research of Salisbury	Salisbury, NC, USA
Fergie, Jaime	Driscoll Children's Hospital	Corpus Christi, TX, USA
Fierro, Carlos	Johnson County Clin-Trials	Lenexa, KS, USA
Finberg, Robert	University of Massachusetts Medical School	Worcester, MA, USA
Finn, Daniel	Kentucky Pediatric/Adult Research	Bardstown, KY, USA
Fitz-Patrick, David	East-West Medical Research Institute	Honolulu, HI, USA
Fortmann, Stephen	Kaiser Permanente Center for Health Research	Portland, OR, USA
Fouche, Leon	Tamotie Medical Centre	Thabazimbi, South Africa
Fragoso, Veronica	Texas Center for Drug Development	Houston, TX, USA
Freneck, Robert	Cincinnati Children's Hospital	Cincinnati, OH, USA
Fried, David	Omega Medical Research	Warwick, RI, USA
Fuller, Gregory	Ventavia Research Group	Keller, TX, USA
Fussell, Suzanne	Long Beach Clinical Trials Services	Long Beach, CA, USA
Galler, Greg	Kelsey-Seybold Clinic	Houston, TX, USA
Garcia-Diaz, Julia	Ochsner Health	New Orleans, LA, USA
Garner, Fredric	PI-Coor Clinical Research	Burke, VA, USA
Gentry, Andrew	Bozeman Health Clinical Research	Bozeman, MT, USA
Geßner, Christian	POIS Leipzig	Leipzig, Germany
Glover, Richard	Alliance for Multispecialty Research	Newton, KS, USA
Govind, Uttam	Randles Road Medical Centre	Durban, South Africa
Greenbaum, Carla	Benaroya Research Institute at Virginia Mason	Seattle, WA, USA
Greenberg, Richard	University of Kentucky College of Medicine	Lexington, KY, USA
Griffin, Carl	Lynn Institute	Oklahoma City, OK, USA
Grubb, Stephen	Main Street Physicians	Little River, SC, USA
Grunstra, Bernard	PMG Research of Bristol	Bristol, TN, USA
Guimarães de Noronha, Tatiana	FioCruz	Rio de Janeiro, Brazil
Güner, Rahmet	Ankara City Hospital	Ankara, Turkey
Günzel, Andrea	Klinische Forschung Dresden	Dresden, Germany
Hachigian, Greg	Benchmark Research	Sacramento, CA, USA
Hammit, Laura	Johns Hopkins Center for American Indian Health	Whiteriver, AZ, USA
	Johns Hopkins Center for American Indian Health	Chinle, AZ, USA
	Johns Hopkins Center for American Indian Health	Shiprock, NM, USA
	Johns Hopkins Center for American Indian Health	Gallup, NM, USA

Harper, Charles	Meridian Clinical Research	Norfolk, NE, USA
Harper, Wayne	Wake Research	Raleigh, NC, USA
Harrison, Christopher	Children's Mercy Hospital	Kansas City, MO, USA
Hartard, Manfred	Centrum fuer Diagnostik und Gesundheit CDG	München, Germany
Hartman, Aaron	Virginia Research Center	Midlothian, VA, USA
Heller, Robert	Bayview Research Group	Valley Village, CA, USA
Hempstead, Kenneth	Kaiser Permanente	Roseville, CA, USA
Hendrix, Ernest	North Alabama Research Center	Athens, AL, USA
Herrington, Darrell	Benchmark Research	San Angelo, TX, USA
Hoberman, Alejandro	Children's Hospital of Pittsburgh	Pittsburgh, PA, USA
Horacek, Thomas	Forschungszentrum Ruhr	Witten, Germany
Hummel, Matthew	Fountain Hills Family Practice	Fountain Hills, AZ, USA
Hurley, Donald	Medical Research South	Charleston, SC, USA
Jackson, Lisa	Kaiser Permanente	Seattle, WA, USA
Janoff, Edward	University of Colorado - Anschutz Medical Campus	Aurora, CO, USA
Jennings, Timothy	Clinical Research Professionals	Chesterfield, MO, USA
Johnson, David	Bay Pines VA Healthcare System	Bay Pines, FL, USA
Kallas, Esper	Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo	Sao Paulo, Brazil
Kankam, Martin	Vince and Associates Clinical Research	Overland Park, KS, USA
Karabay, Oğuz	Sakarya University Faculty of Medicine	Sakarya, Turkey
Kaster, Steven	Confluence Health/Wenatchee Valley Hospital & Clinics	Wenatchee, WA, USA
Katzman, Steven	Michigan Center for Medical Research	Farmington Hills, MI, USA
Keller, Claus	Praxis Dr. med. Claus Keller	Frankfurt, Germany
Kingsley, Jeffrey	Columbus Regional Research Institute	Columbus, GA, USA
Klein, Christiane	Gemeinschaftspraxis für Allgemeinmedizin Dr. med. Elke Iburg, Christiane Klein	Frankfurt, Germany
Klein, Nicola	Kaiser Permanente	Santa Clara, CA, USA
	Kaiser Permanente	Sacramento, CA, USA
	Kaiser Permanente	Oakland, CA, USA
Klein, Tracy	Heartland Research Associates	Wichita, KS, USA
Koch, Mark	Ventavia Research Group	Fort Worth, TX, USA
Köksal, İftahar	Acibadem University Hospital Atakent	Istanbul, Turkey
Koren, Michael	Jacksonville Center for Clinical Research	Jacksonville, FL, USA
Korten, Volkan	Marmara University Istanbul Pendik Training and Research Hospital	Istanbul, Turkey
Kowalski, Todd	Gundersen Health System	La Crosse, WI, USA
Kutner, Mark	Suncoast Research Group	Miami, FL, USA
Lee, Marcus	Trinity Clinical Research	Tullahoma, TN, USA
Leibowitz, Mark	National Research Institute	Huntingdon Park, CA, USA
Levin, Michael	Clinical Research Center of Nevada	Las Vegas, NV, USA
Libster, Romina	National Scientific and Technical Research Council	Buenos Aires, Argentina
Lillestol, Michael	Lillestol Research	Fargo, ND, USA
Lübbert, Christoph	Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie; Universitätsklinikum Leipzig	Leipzig, Germany
Lucasti, Christopher	South Jersey Infectious Disease	Somers Point, NJ, USA
Luttermann, Matthias	Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher	Stuhr, Germany
Makram, Nicole	Kaiser Permanente	Sacramento, CA, USA

Mangune, Edwin	Center for Clinical Trials	Paramount, CA, USA
Manning, Mary Beth	Velocity Clinical Research	Cleveland, OH, USA
Martin, Earl	Martin Diagnostic Clinic	Tomball, TX, USA
Matherne, Paul	MedPharmics	Gulfport, MS, USA
Matson, Mark	Prism Clinical Research	St Paul, MN, USA
Mayer, Renae	Lynn Institute of Tulsa	Tulsa, OK, USA
McMurray, James	Medical Affiliated Research Center (MARC)	Huntsville, AL, USA
Mert, Ali	Medipol University Hospital	Istanbul, Turkey
Middleton, Randle	Optimal Research	Huntsville, AL, USA
Miller, Randall	Horizon Research Group of Opelousas	Eunice, LA, USA
Mitha, Essack	Newtown Clinical Research	Johannesburg, South Africa
Möckesch, Beate	Atriumpraxis	Weinheim, Germany
Morawski, Emily	Holston Medical Group	Kingsport, TN, USA
Moreira, Edson	Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation	Bahia, Brazil
Mullane, Kathleen	University of Chicago Medicine	Chicago, IL, USA
Murray, Alexander	PharmQuest	Greensboro, NC, USA
Mussaji, Murtaza	LinQ Research	Houston, TX, USA
Musungaie, Dany	Jongaie Research	Pretoria, South Africa
Nell, Haylene	Tiervlei Trial Centre, Karl Bremer Hospital	Cape Town, South Africa
Odekirk, Larry	Lynn Institute of Denver	Denver, CO, USA
Ogbuagu, Onyema	Yale University School of Medicine	New Haven, CT, USA
Paolino, Kristopher	State University of New York, Upstate Medical University	Syracuse, NY, USA
Patel, Rahul	Meridian Clinical Research	Rockville, MD, USA
Patel, Suchet	Regional Clinical Research	Endwell, NY, USA
Paules, Catharine	Penn State Health	Hershey, PA, USA
Peterson, James	J. Lewis Research	Salt Lake City, UT, USA
Pickrell, Paul	Tekton Research	Austin, TX, USA
Pletz, Mathias	Institut für Infektionsmedizin und Krankenhaushygiene Universitätsklinikum Jena	Jena, Germany
Polack, Fernando	Fundacion INFANT	Buenos Aires, Argentina
Poretz, Donald	Clinical Alliance for Research and Education	Annandale, VA, USA
Purighalla, Raman	Preferred Primary Care Physicians	Pittsburgh, PA, USA
Raad, George	PMG Research of Charlotte	Charlotte, NC, USA
Randall, William	PriMed Clinical Research	Dayton, OH, USA
Rankin, Bruce	Accel Research Sites - DeLand Clinical Research Unit	DeLand, FL, USA
Rausch, Michael	Heartland Research	Augusta, KS, USA
Reynolds, Steven	Collaborative Neuroscience Network	Long Beach, CA, USA
Riesenberg, Robert	Atlanta Center for Medical Research	Atlanta, GA, USA
Rizzardi, Barbara	Advanced Clinical Research	West Jordan, UT, USA
Rodriguez, Hector	Acevedo Clinical Research Associates	Miami, FL, USA
Rosen, Jeffrey	Clinical Research of South Florida	Coral Gables, FL, USA
Rubino, John	Raleigh Medical Group, PA	Raleigh, NC, USA
Rupp, Richard	University of Texas	Galveston, TX, USA
Saiger, Salma	Research Across America	Mesquite, TX, USA
Salata, Robert	University Hospitals Cleveland Medical Center	Cleveland, OH, USA
Saleh, Jamshid	Northern California Neurological Surgery	Redding, CA, USA
Schaefer, Axel	Medizentrum Essen Borbeck	Essen, Germany

Schear, Martin	Dayton Clinical Research	Dayton, OH, USA
Schultz, Armin	CRS Clinical Research Services Mannheim	Mannheim, Germany
Schwartz, Howard	Research Centers of America	Hollywood, FL, USA
Schwarz, Tino	Stiftung Juliusspital Würzburg	Würzburg, Germany
Segall, Nathan	Clinical Research Atlanta	Stockbridge, GA, USA
Seger, William	HealthFirst Medical Group	Fort Worth, TX, USA
Senders, Shelly	Senders Pediatrics	South Euclid, OH, USA
Sha, Beverly	Rush University Medical Center	Chicago, IL, USA
Sharp, Stephan	Clinical Research Associates	Nashville, TN, USA
Shoffner, Sylvia	PMG Research of Cary	Cary, NC, USA
Sigal, Helena	SIBAmед Studienzentrum	Leipzig, Germany
Simsek Yavuz, Serap	İstanbul Faculty of Medicine, İstanbul University	Istanbul, Turkey
Sligh, Teresa	Providence Clinical Research	North Hollywood, CA, USA
Smith, William	New Orleans Center for Clinical Research	New Orleans, LA, USA
Sprinz, Eduardo	Hospital de Clínicas de Porto Alegre	Porto Alegre, Brazil
Stacey, Helen	Diablo Clinical Research	Walnut Creek, CA, USA
Starling, Carlos	Hospital Vera Cruz	Belo Horizonte, Brazil
Stephens, Michael	Fleming Island Center for Clinical Research	Fleming Island, FL, USA
Studdard, Harry	Coastal Clinical Research	Mobile, AL, USA
Sturm, Kerstin	EMOVIS	Berlin, Germany
Tabak, Fehmi	Istanbul University Cerrahpaşa Medical School	Istanbul, Turkey
Talaat, Kawsar	Johns Hopkins School of Medicine	Baltimore, MD, USA
Tarro, Jimmie	Columbia Research Group	Portland, OR, USA
Thomas, Stephen	State University of New York, Upstate Medical University	Syracuse, NY, USA
Towner, William	Kaiser Permanente	Los Angeles, CA, USA
Tran, Van	Ventavia Research Group	Houston, TX, USA
Ünal, Serhat	Hacettepe University	Ankara, Turkey
Usdan, Lisa	CNS Healthcare	Memphis, TN, USA
Vanchiere, John	Louisiana State University Health Shreveport	Shreveport, LA, USA
Varano, Susann	Clinical Research Consulting	Milford, CT, USA
von Engelhardt, Charlotte	Klinische Forschung Schwerin	Schwerin, Germany
Wadell, Chad	St. Joseph Heritage Healthcare	Mission Viejo, CA, USA
Wadsworth, L. Tyler	Sundance Clinical Research	St Louis, MO, USA
Walter, Chip	Duke Human Vaccine Institute	Durham, NC, USA
Wang, Dee Dee	Henry Ford Heart and Vascular Institute	Detroit, MI, USA
Wappner, Diego	Fundacion INFANT	Buenos Aires, Argentina
Welte, Tobias	Medizinische Hochschule Hannover	Hannover, Germany
Westheimer Cavalcante, Adilson Joaquim	Centro Multidisciplinar de Estudos Clínicos CEMEC	Sao Paolo, Brazil
Whiles, Rick	Holston Medical Group	Bristol, TN, USA
White, Alexander	Progressive Medical Research	Port Orange, FL, USA
Williams, Hayes	Achieve Clinical Research	Birmingham, AL, USA
Wilson, Jonathan	Piedmont Medical Research of Winston-Salem	Winston-Salem, NC, USA
Winkle, Peter	Anaheim Clinical Trials	Anaheim, CA, USA
Winokur, Patricia	University of Iowa	Iowa City, IA, USA
Wofford, Scott	Arkansas Gastroenterology	North Little Rock, AR, USA
Wolf, Thomas	Prairie Fields Family Medicine	Fremont, NE, USA

Wolff, Priscila	IPBClin	Rio de Janeiro, Brazil
Yakish, Jack	Westminster Family Medicine	Erie, PA, USA
Yıldırım, Taner	Prof. Dr.Cemil Tascioğlu City Hospital	Istanbul, Turkey
Yozviak, Joseph	Lehigh Valley Hospital Cedar Crest	Allentown, PA, USA
Zerbini, Cristiano	Centro Paulista de Investigação Clínica - CEPIC	Sao Paolo, Brazil

Figure/Table Number	Figure/Table Title	Population(s)/Sample Size	Explanation
Figure 1	Disposition of participants (CONSORT)	All enrolled population ~37,706 “main safety subset”	All randomized ≥16 years of age, N=43,548 <ul style="list-style-type: none"> [minus 99 non-vaccinated, 1 no ICD] Vaccinated N=43,448 Main safety subset (N=37,706) needed to have been enrolled by October 9, 2020 for EUA application
Figure 2	Local and Systemic Reactions Reported within 7 Days after Receipt of 30 µg BNT162b2 or Placebo by Age Group	Reactogenicity subset of ≥16 years old N=8,183	Per protocol
Figure 3	Efficacy of BNT162b2 against COVID-19 Occurrence after Dose 1	N=43,355 (modified intention-to-treat)	All randomized ≥12 years of age N= 43,651 <ul style="list-style-type: none"> [minus 99 non-vaccinated, 1 no ICD] Vaccinated (dose 1 efficacy) N=43,551 <ul style="list-style-type: none"> [minus 196 HIV+] All efficacy N=43,355
Table 1	Demographics	N=37,706 main safety subset	As above
Table 2	Vaccine Efficacy against COVID-19 from 7 Days after Dose 2 [Primary Endpoints]	1st primary efficacy endpoint: Includes those without infection at baseline (N=36,523) 2nd primary efficacy endpoint: Includes those with and without infection at baseline (N=40,137)	Evaluable population: <ul style="list-style-type: none"> received 2 vaccinations as randomized no major protocol deviations Excludes HIV+
Table 3	Vaccine Efficacy Overall and by Subgroup in Participants without Evidence of Infection Prior to 7 Days After Dose 2	N=36,523 (same as 1st primary endpoint)	
Table S2	Baseline Comorbidities	N=37,706 main safety subset	
Table S3	Participants Reporting at Least 1 Adverse Event From Dose 1 (All Enrolled Participants)	N=43,252	Vaccinated N=43,448 minus 196 HIV+
Table S4	Vaccine Efficacy from 7 Days After Dose 2 by Underlying Comorbidities among Participants without Evidence of Infection Prior to 7 Days after Dose 2	N=36,523 (same as 1st primary endpoint)	
Table S5	Vaccine Efficacy of Severe COVID-19 Occurrence after Dose 1 (All-Available Efficacy Population)	N=43,355 (all evaluable efficacy)	See comments to Figure 3

Table S1 | Explanation of the Changes in Denominator Numbers in Various Analyses.

	BNT162b2 (30 µg) (N ^a =18860)	Placebo (N ^a =18846)	Total (N ^a =37706)
Charlson Comorbidity Index Category	n^b (%)	n^b (%)	n^b (%)
Participants with any Charlson comorbidity	3934 (20.9)	3809 (20.2)	7743 (20.5)
AIDS/HIV	59 (0.3)	62 (0.3)	121 (0.3)
Any malignancy	733 (3.9)	662 (3.5)	1395 (3.7)
Cerebrovascular disease	195 (1.0)	166 (0.9)	361 (1.0)
Chronic pulmonary disease	1478 (7.8)	1453 (7.7)	2931 (7.8)
Congestive heart failure	88 (0.5)	83 (0.4)	171 (0.5)
Dementia	7 (0.0)	11 (0.1)	18 (0.0)
Diabetes with chronic complication	99 (0.5)	113 (0.6)	212 (0.6)
Diabetes without chronic complication	1473 (7.8)	1478 (7.8)	2951 (7.8)
Hemiplegia or paraplegia	13 (0.1)	21 (0.1)	34 (0.1)
Leukemia	12 (0.1)	10 (0.1)	22 (0.1)
Lymphoma	22 (0.1)	32 (0.2)	54 (0.1)
Metastatic solid tumor	4 (0.0)	3 (0.0)	7 (0.0)
Mild liver disease	125 (0.7)	89 (0.5)	214 (0.6)
Moderate or severe liver disease	1 (0.0)	2 (0.0)	3 (0.0)
Myocardial infarction	194 (1.0)	188 (1.0)	382 (1.0)
Peptic ulcer disease	52 (0.3)	71 (0.4)	123 (0.3)
Peripheral vascular disease	124 (0.7)	117 (0.6)	241 (0.6)
Renal disease	123 (0.7)	133 (0.7)	256 (0.7)
Rheumatic disease	62 (0.3)	56 (0.3)	118 (0.3)

Table S2 | Baseline Comorbidities. Baseline comorbid conditions are classified according to the Charlson Comorbidity Index (Charlson M, TP Szatrowski, J Peterson, J. Gold. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245-51.). a. N = number of participants in the specified group. This value is the denominator for the percentage calculations. b. n = Number of participants with the specified characteristic. Participants with multiple occurrences within each category are counted only once. For ‘Participants with any Charlson comorbidity’, n = number of participants reporting at least 1 occurrence of any Charlson comorbidity.

	BNT162b2 (30 µg) (N^a=21621)	Placebo (N^a=21631)
Adverse Event	n^b (%)	n^b (%)
Any event	5770 (26.7)	2638 (12.2)
Related ^c	4484 (20.7)	1095 (5.1)
Severe	240 (1.1)	139 (0.6)
Life-threatening	21 (0.1)	24 (0.1)
Any serious adverse event	126 (0.6)	111 (0.5)
Related ^c	4 (0.0)	0
Severe	71 (0.3)	68 (0.3)
Life-threatening	21 (0.1)	23 (0.1)
Any adverse event leading to withdrawal	37 (0.2)	30 (0.1)
Related ^c	16 (0.1)	9 (0.0)
Severe	13 (0.1)	9 (0.0)
Life-threatening	3 (0.0)	6 (0.0)
Death	2 (0.0)	4 (0.0)

Table S3 | Participants Reporting at Least 1 Adverse Event from Dose 1 (All Enrolled Participants). The ‘all enrolled’ population included all participants who received at least 1 dose of vaccine irrespective of follow-up time. a. N = number of participants in the specified group. This value is the denominator for the percentage calculations. b. n = Number of participants reporting at least 1 occurrence of the specified event category. For ‘any event’, n = the number of participants reporting at least 1 occurrence of any event. c. Assessed by the investigator as related to investigational product.

Efficacy Endpoint Subgroup	BNT162b2 (30 µg) (N ^a =18198)		Placebo (N ^a =18325)		VE (%)	(95% CI ^e)
	n1 ^b	Surveillance Time ^c (n2 ^d)	n1 ^b	Surveillance Time ^c (n2 ^d)		
Overall	8	2.214 (17411)	162	2.222 (17511)	95.0	(90.0, 97.9)
At risk ^f						
Yes	4	1.025 (8030)	86	1.025 (8029)	95.3	(87.7, 98.8)
No	4	1.189 (9381)	76	1.197 (9482)	94.7	(85.9, 98.6)
Age group (years) and at risk						
16–64 and not at risk	4	0.962 (7671)	69	0.964 (7701)	94.2	(84.4, 98.5)
16–64 and at risk	3	0.744 (5878)	74	0.746 (5917)	95.9	(87.6, 99.2)
≥65 and not at risk	0	0.227 (1701)	7	0.233 (1771)	100.0	(29.0, 100.0)
≥65 and at risk	1	0.281 (2147)	12	0.279 (2109)	91.7	(44.2, 99.8)
Obese ^g						
Yes	3	0.763 (6000)	67	0.782 (6103)	95.4	(86.0, 99.1)
No	5	1.451 (11406)	95	1.439 (11404)	94.8	(87.4, 98.3)
Age group (years) and obese						
16–64 and not obese	4	1.107 (8811)	83	1.101 (8825)	95.2	(87.3, 98.7)
16–64 and obese	3	0.598 (4734)	60	0.609 (4789)	94.9	(84.4, 99.0)
≥65 and not obese	1	0.343 (2582)	12	0.338 (2567)	91.8	(44.5, 99.8)
≥65 and obese	0	0.165 (1265)	7	0.173 (1313)	100.0	(27.1, 100.0)

Table S4 | Vaccine Efficacy from 7 Days after Dose 2 by Underlying Comorbidities among Participants without Evidence of Infection Prior to 7 Days after Dose 2. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period. a. N = number of participants in the specified group. b. n1 = Number of participants meeting the endpoint definition. c. Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period. d. n2 = Number of participants at risk for the endpoint. e. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time. f. At risk is defined as having at least one of the Charlson Comorbidity Index categories or obesity (body mass index [BMI] ≥ 30 kg/m²). g. Obese is defined as BMI ≥ 30 kg/m².

Efficacy Endpoint Subgroup	BNT162b2 (30 µg) (N ^a =21669)		Placebo (N ^a =21686)		VE (%)	(95% CI ^e)
	n1 ^b	Surveillance Time ^c (n2 ^d)	n1 ^b	Surveillance Time ^c (n2 ^d)		
Severe COVID-19 occurrence after Dose 1	1	4.021 (21314)	9	4.006 (21259)	88.9	(20.1, 99.7)
After Dose 1 to before Dose 2	0		4		100.0	(-51.5, 100.0)
Dose 2 to 7 days after Dose 2	0		1		100.0	(-3800.0, 100.0)
≥7 Days after Dose 2	1		4		75.0	(-152.6, 99.5)

Table S5 | Vaccine Efficacy of Severe COVID-19 Occurrence after Dose 1 (All-Available Efficacy Population). a. N = number of participants in the specified group. b. n1 = Number of participants meeting the endpoint definition. c. Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for COVID-19 case accrual is from Dose 1 to the end of the surveillance period. d. n2 = Number of participants at risk for the endpoint. e. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method (adjusted for surveillance time for overall row).